Trials / Completed
CompletedNCT00306553
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYT004-MelQbG10 |
Timeline
- First posted
- 2006-03-24
- Last updated
- 2006-09-19
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00306553. Inclusion in this directory is not an endorsement.